nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—Ulcerative stomatitis—Dactinomycin—muscle cancer	0.0365	0.0365	CcSEcCtD
Darifenacin—Obstructive airways disorder—Methotrexate—muscle cancer	0.0321	0.0321	CcSEcCtD
Darifenacin—Ulcerative stomatitis—Methotrexate—muscle cancer	0.0158	0.0158	CcSEcCtD
Darifenacin—Mouth ulceration—Dactinomycin—muscle cancer	0.0152	0.0152	CcSEcCtD
Darifenacin—Ulcerative stomatitis—Doxorubicin—muscle cancer	0.0137	0.0137	CcSEcCtD
Darifenacin—Mouth ulceration—Vincristine—muscle cancer	0.0136	0.0136	CcSEcCtD
Darifenacin—Mouth ulceration—Etoposide—muscle cancer	0.011	0.011	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Dactinomycin—muscle cancer	0.011	0.011	CcSEcCtD
Darifenacin—Urinary retention—Vincristine—muscle cancer	0.0104	0.0104	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.00983	0.00983	CcSEcCtD
Darifenacin—Stomatitis—Dactinomycin—muscle cancer	0.00918	0.00918	CcSEcCtD
Darifenacin—Erectile dysfunction—Vincristine—muscle cancer	0.00869	0.00869	CcSEcCtD
Darifenacin—Pharyngitis—Dactinomycin—muscle cancer	0.00839	0.00839	CcSEcCtD
Darifenacin—Stomatitis—Vincristine—muscle cancer	0.0082	0.0082	CcSEcCtD
Darifenacin—Sweating—Vincristine—muscle cancer	0.00807	0.00807	CcSEcCtD
Darifenacin—Erythema multiforme—Dactinomycin—muscle cancer	0.00799	0.00799	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Etoposide—muscle cancer	0.0078	0.0078	CcSEcCtD
Darifenacin—Hallucination—Vincristine—muscle cancer	0.00751	0.00751	CcSEcCtD
Darifenacin—Urinary tract disorder—Vincristine—muscle cancer	0.00746	0.00746	CcSEcCtD
Darifenacin—Urethral disorder—Vincristine—muscle cancer	0.0074	0.0074	CcSEcCtD
Darifenacin—Vaginal inflammation—Methotrexate—muscle cancer	0.0073	0.0073	CcSEcCtD
Darifenacin—Thinking abnormal—Doxorubicin—muscle cancer	0.0069	0.0069	CcSEcCtD
Darifenacin—Cough increased—Doxorubicin—muscle cancer	0.0069	0.0069	CcSEcCtD
Darifenacin—Vaginal infection—Methotrexate—muscle cancer	0.00689	0.00689	CcSEcCtD
Darifenacin—Angiopathy—Vincristine—muscle cancer	0.00685	0.00685	CcSEcCtD
Darifenacin—Infestation NOS—Etoposide—muscle cancer	0.00682	0.00682	CcSEcCtD
Darifenacin—Infestation—Etoposide—muscle cancer	0.00682	0.00682	CcSEcCtD
Darifenacin—Mediastinal disorder—Vincristine—muscle cancer	0.00681	0.00681	CcSEcCtD
Darifenacin—Stomatitis—Etoposide—muscle cancer	0.00664	0.00664	CcSEcCtD
Darifenacin—Mental disorder—Vincristine—muscle cancer	0.00662	0.00662	CcSEcCtD
Darifenacin—Mouth ulceration—Methotrexate—muscle cancer	0.0066	0.0066	CcSEcCtD
Darifenacin—Bladder pain—Methotrexate—muscle cancer	0.0066	0.0066	CcSEcCtD
Darifenacin—Back pain—Vincristine—muscle cancer	0.00636	0.00636	CcSEcCtD
Darifenacin—Vaginal inflammation—Doxorubicin—muscle cancer	0.00632	0.00632	CcSEcCtD
Darifenacin—Urinary tract disorder—Etoposide—muscle cancer	0.00604	0.00604	CcSEcCtD
Darifenacin—Oedema—Dactinomycin—muscle cancer	0.00601	0.00601	CcSEcCtD
Darifenacin—Urethral disorder—Etoposide—muscle cancer	0.006	0.006	CcSEcCtD
Darifenacin—Infection—Dactinomycin—muscle cancer	0.00597	0.00597	CcSEcCtD
Darifenacin—Vaginal infection—Doxorubicin—muscle cancer	0.00597	0.00597	CcSEcCtD
Darifenacin—Dry eye—Doxorubicin—muscle cancer	0.00584	0.00584	CcSEcCtD
Darifenacin—Erythema multiforme—Etoposide—muscle cancer	0.00578	0.00578	CcSEcCtD
Darifenacin—Eye disorder—Etoposide—muscle cancer	0.00572	0.00572	CcSEcCtD
Darifenacin—Mouth ulceration—Doxorubicin—muscle cancer	0.00571	0.00571	CcSEcCtD
Darifenacin—Bladder pain—Doxorubicin—muscle cancer	0.00571	0.00571	CcSEcCtD
Darifenacin—Hypertension—Vincristine—muscle cancer	0.00568	0.00568	CcSEcCtD
Darifenacin—Visual disturbance—Methotrexate—muscle cancer	0.00559	0.00559	CcSEcCtD
Darifenacin—Angiopathy—Etoposide—muscle cancer	0.00555	0.00555	CcSEcCtD
Darifenacin—Mediastinal disorder—Etoposide—muscle cancer	0.00551	0.00551	CcSEcCtD
Darifenacin—Abnormal vision—Doxorubicin—muscle cancer	0.00551	0.00551	CcSEcCtD
Darifenacin—Mental disability—Doxorubicin—muscle cancer	0.00548	0.00548	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00547	0.00547	CcSEcCtD
Darifenacin—Cerebrovascular accident—Methotrexate—muscle cancer	0.00541	0.00541	CcSEcCtD
Darifenacin—Anaphylactic shock—Vincristine—muscle cancer	0.00537	0.00537	CcSEcCtD
Darifenacin—Oedema—Vincristine—muscle cancer	0.00537	0.00537	CcSEcCtD
Darifenacin—Infection—Vincristine—muscle cancer	0.00533	0.00533	CcSEcCtD
Darifenacin—Nervous system disorder—Vincristine—muscle cancer	0.00526	0.00526	CcSEcCtD
Darifenacin—Dysgeusia—Etoposide—muscle cancer	0.00522	0.00522	CcSEcCtD
Darifenacin—Hyperhidrosis—Vincristine—muscle cancer	0.00519	0.00519	CcSEcCtD
Darifenacin—Back pain—Etoposide—muscle cancer	0.00515	0.00515	CcSEcCtD
Darifenacin—Pain—Dactinomycin—muscle cancer	0.00514	0.00514	CcSEcCtD
Darifenacin—Feeling abnormal—Dactinomycin—muscle cancer	0.00495	0.00495	CcSEcCtD
Darifenacin—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00491	0.00491	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00489	0.00489	CcSEcCtD
Darifenacin—Insomnia—Vincristine—muscle cancer	0.00485	0.00485	CcSEcCtD
Darifenacin—Breast disorder—Methotrexate—muscle cancer	0.00479	0.00479	CcSEcCtD
Darifenacin—Abdominal pain—Dactinomycin—muscle cancer	0.00475	0.00475	CcSEcCtD
Darifenacin—Loss of consciousness—Etoposide—muscle cancer	0.00468	0.00468	CcSEcCtD
Darifenacin—Cerebrovascular accident—Doxorubicin—muscle cancer	0.00468	0.00468	CcSEcCtD
Darifenacin—Cough—Etoposide—muscle cancer	0.00465	0.00465	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Vincristine—muscle cancer	0.00463	0.00463	CcSEcCtD
Darifenacin—Hypertension—Etoposide—muscle cancer	0.0046	0.0046	CcSEcCtD
Darifenacin—Pain—Vincristine—muscle cancer	0.00459	0.00459	CcSEcCtD
Darifenacin—Constipation—Vincristine—muscle cancer	0.00459	0.00459	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.0045	0.0045	CcSEcCtD
Darifenacin—Face oedema—Doxorubicin—muscle cancer	0.00443	0.00443	CcSEcCtD
Darifenacin—Hypersensitivity—Dactinomycin—muscle cancer	0.00442	0.00442	CcSEcCtD
Darifenacin—Gastrointestinal pain—Vincristine—muscle cancer	0.00439	0.00439	CcSEcCtD
Darifenacin—Confusional state—Etoposide—muscle cancer	0.00438	0.00438	CcSEcCtD
Darifenacin—Anaphylactic shock—Etoposide—muscle cancer	0.00435	0.00435	CcSEcCtD
Darifenacin—Infection—Etoposide—muscle cancer	0.00432	0.00432	CcSEcCtD
Darifenacin—Asthenia—Dactinomycin—muscle cancer	0.00431	0.00431	CcSEcCtD
Darifenacin—Tachycardia—Etoposide—muscle cancer	0.00424	0.00424	CcSEcCtD
Darifenacin—Abdominal pain—Vincristine—muscle cancer	0.00424	0.00424	CcSEcCtD
Darifenacin—Skin disorder—Etoposide—muscle cancer	0.00422	0.00422	CcSEcCtD
Darifenacin—Erectile dysfunction—Methotrexate—muscle cancer	0.00422	0.00422	CcSEcCtD
Darifenacin—Dry skin—Doxorubicin—muscle cancer	0.0042	0.0042	CcSEcCtD
Darifenacin—Hyperhidrosis—Etoposide—muscle cancer	0.0042	0.0042	CcSEcCtD
Darifenacin—Breast disorder—Doxorubicin—muscle cancer	0.00415	0.00415	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.00413	0.00413	CcSEcCtD
Darifenacin—Diarrhoea—Dactinomycin—muscle cancer	0.00411	0.00411	CcSEcCtD
Darifenacin—Infestation NOS—Methotrexate—muscle cancer	0.00408	0.00408	CcSEcCtD
Darifenacin—Infestation—Methotrexate—muscle cancer	0.00408	0.00408	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.00405	0.00405	CcSEcCtD
Darifenacin—Stomatitis—Methotrexate—muscle cancer	0.00398	0.00398	CcSEcCtD
Darifenacin—Influenza—Doxorubicin—muscle cancer	0.00396	0.00396	CcSEcCtD
Darifenacin—Hypersensitivity—Vincristine—muscle cancer	0.00395	0.00395	CcSEcCtD
Darifenacin—Sweating—Methotrexate—muscle cancer	0.00391	0.00391	CcSEcCtD
Darifenacin—Dyspnoea—Etoposide—muscle cancer	0.00388	0.00388	CcSEcCtD
Darifenacin—Somnolence—Etoposide—muscle cancer	0.00386	0.00386	CcSEcCtD
Darifenacin—Asthenia—Vincristine—muscle cancer	0.00385	0.00385	CcSEcCtD
Darifenacin—Vomiting—Dactinomycin—muscle cancer	0.00382	0.00382	CcSEcCtD
Darifenacin—Bronchitis—Doxorubicin—muscle cancer	0.00381	0.00381	CcSEcCtD
Darifenacin—Rash—Dactinomycin—muscle cancer	0.00379	0.00379	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Etoposide—muscle cancer	0.00375	0.00375	CcSEcCtD
Darifenacin—Constipation—Etoposide—muscle cancer	0.00372	0.00372	CcSEcCtD
Darifenacin—Pain—Etoposide—muscle cancer	0.00372	0.00372	CcSEcCtD
Darifenacin—Diarrhoea—Vincristine—muscle cancer	0.00367	0.00367	CcSEcCtD
Darifenacin—Pharyngitis—Methotrexate—muscle cancer	0.00364	0.00364	CcSEcCtD
Darifenacin—Urinary tract disorder—Methotrexate—muscle cancer	0.00362	0.00362	CcSEcCtD
Darifenacin—Weight increased—Doxorubicin—muscle cancer	0.00361	0.00361	CcSEcCtD
Darifenacin—Urethral disorder—Methotrexate—muscle cancer	0.00359	0.00359	CcSEcCtD
Darifenacin—Feeling abnormal—Etoposide—muscle cancer	0.00358	0.00358	CcSEcCtD
Darifenacin—Nausea—Dactinomycin—muscle cancer	0.00357	0.00357	CcSEcCtD
Darifenacin—Gastrointestinal pain—Etoposide—muscle cancer	0.00355	0.00355	CcSEcCtD
Darifenacin—Dizziness—Vincristine—muscle cancer	0.00355	0.00355	CcSEcCtD
Darifenacin—Infestation NOS—Doxorubicin—muscle cancer	0.00353	0.00353	CcSEcCtD
Darifenacin—Infestation—Doxorubicin—muscle cancer	0.00353	0.00353	CcSEcCtD
Darifenacin—Visual impairment—Methotrexate—muscle cancer	0.00353	0.00353	CcSEcCtD
Darifenacin—Erythema multiforme—Methotrexate—muscle cancer	0.00347	0.00347	CcSEcCtD
Darifenacin—Stomatitis—Doxorubicin—muscle cancer	0.00345	0.00345	CcSEcCtD
Darifenacin—Abdominal pain—Etoposide—muscle cancer	0.00344	0.00344	CcSEcCtD
Darifenacin—Urinary tract infection—Doxorubicin—muscle cancer	0.00344	0.00344	CcSEcCtD
Darifenacin—Eye disorder—Methotrexate—muscle cancer	0.00342	0.00342	CcSEcCtD
Darifenacin—Vomiting—Vincristine—muscle cancer	0.00341	0.00341	CcSEcCtD
Darifenacin—Sweating—Doxorubicin—muscle cancer	0.00339	0.00339	CcSEcCtD
Darifenacin—Rash—Vincristine—muscle cancer	0.00338	0.00338	CcSEcCtD
Darifenacin—Dermatitis—Vincristine—muscle cancer	0.00338	0.00338	CcSEcCtD
Darifenacin—Headache—Vincristine—muscle cancer	0.00336	0.00336	CcSEcCtD
Darifenacin—Angiopathy—Methotrexate—muscle cancer	0.00332	0.00332	CcSEcCtD
Darifenacin—Sinusitis—Doxorubicin—muscle cancer	0.00332	0.00332	CcSEcCtD
Darifenacin—Mediastinal disorder—Methotrexate—muscle cancer	0.0033	0.0033	CcSEcCtD
Darifenacin—Mental disorder—Methotrexate—muscle cancer	0.00321	0.00321	CcSEcCtD
Darifenacin—Hypersensitivity—Etoposide—muscle cancer	0.0032	0.0032	CcSEcCtD
Darifenacin—Nausea—Vincristine—muscle cancer	0.00319	0.00319	CcSEcCtD
Darifenacin—Rhinitis—Doxorubicin—muscle cancer	0.00318	0.00318	CcSEcCtD
Darifenacin—Pharyngitis—Doxorubicin—muscle cancer	0.00315	0.00315	CcSEcCtD
Darifenacin—Urinary tract disorder—Doxorubicin—muscle cancer	0.00313	0.00313	CcSEcCtD
Darifenacin—Oedema peripheral—Doxorubicin—muscle cancer	0.00313	0.00313	CcSEcCtD
Darifenacin—Dysgeusia—Methotrexate—muscle cancer	0.00312	0.00312	CcSEcCtD
Darifenacin—Asthenia—Etoposide—muscle cancer	0.00312	0.00312	CcSEcCtD
Darifenacin—Urethral disorder—Doxorubicin—muscle cancer	0.00311	0.00311	CcSEcCtD
Darifenacin—Back pain—Methotrexate—muscle cancer	0.00309	0.00309	CcSEcCtD
Darifenacin—Pruritus—Etoposide—muscle cancer	0.00308	0.00308	CcSEcCtD
Darifenacin—Visual impairment—Doxorubicin—muscle cancer	0.00306	0.00306	CcSEcCtD
Darifenacin—Vision blurred—Methotrexate—muscle cancer	0.00301	0.00301	CcSEcCtD
Darifenacin—Erythema multiforme—Doxorubicin—muscle cancer	0.003	0.003	CcSEcCtD
Darifenacin—Diarrhoea—Etoposide—muscle cancer	0.00297	0.00297	CcSEcCtD
Darifenacin—Eye disorder—Doxorubicin—muscle cancer	0.00297	0.00297	CcSEcCtD
Darifenacin—Angiopathy—Doxorubicin—muscle cancer	0.00288	0.00288	CcSEcCtD
Darifenacin—Dizziness—Etoposide—muscle cancer	0.00287	0.00287	CcSEcCtD
Darifenacin—Mediastinal disorder—Doxorubicin—muscle cancer	0.00286	0.00286	CcSEcCtD
Darifenacin—Cough—Methotrexate—muscle cancer	0.00278	0.00278	CcSEcCtD
Darifenacin—Mental disorder—Doxorubicin—muscle cancer	0.00278	0.00278	CcSEcCtD
Darifenacin—Vomiting—Etoposide—muscle cancer	0.00276	0.00276	CcSEcCtD
Darifenacin—Rash—Etoposide—muscle cancer	0.00274	0.00274	CcSEcCtD
Darifenacin—Dermatitis—Etoposide—muscle cancer	0.00274	0.00274	CcSEcCtD
Darifenacin—Headache—Etoposide—muscle cancer	0.00272	0.00272	CcSEcCtD
Darifenacin—Flatulence—Doxorubicin—muscle cancer	0.00272	0.00272	CcSEcCtD
Darifenacin—Arthralgia—Methotrexate—muscle cancer	0.00272	0.00272	CcSEcCtD
Darifenacin—Dysgeusia—Doxorubicin—muscle cancer	0.00271	0.00271	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.0027	0.0027	CcSEcCtD
Darifenacin—Back pain—Doxorubicin—muscle cancer	0.00267	0.00267	CcSEcCtD
Darifenacin—Confusional state—Methotrexate—muscle cancer	0.00263	0.00263	CcSEcCtD
Darifenacin—Anaphylactic shock—Methotrexate—muscle cancer	0.0026	0.0026	CcSEcCtD
Darifenacin—Vision blurred—Doxorubicin—muscle cancer	0.0026	0.0026	CcSEcCtD
Darifenacin—Infection—Methotrexate—muscle cancer	0.00259	0.00259	CcSEcCtD
Darifenacin—Nausea—Etoposide—muscle cancer	0.00258	0.00258	CcSEcCtD
Darifenacin—Nervous system disorder—Methotrexate—muscle cancer	0.00255	0.00255	CcSEcCtD
Darifenacin—Skin disorder—Methotrexate—muscle cancer	0.00253	0.00253	CcSEcCtD
Darifenacin—Hyperhidrosis—Methotrexate—muscle cancer	0.00252	0.00252	CcSEcCtD
Darifenacin—Syncope—Doxorubicin—muscle cancer	0.00248	0.00248	CcSEcCtD
Darifenacin—Palpitations—Doxorubicin—muscle cancer	0.00244	0.00244	CcSEcCtD
Darifenacin—Loss of consciousness—Doxorubicin—muscle cancer	0.00243	0.00243	CcSEcCtD
Darifenacin—Cough—Doxorubicin—muscle cancer	0.00241	0.00241	CcSEcCtD
Darifenacin—Hypertension—Doxorubicin—muscle cancer	0.00238	0.00238	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00237	0.00237	CcSEcCtD
Darifenacin—Insomnia—Methotrexate—muscle cancer	0.00235	0.00235	CcSEcCtD
Darifenacin—Arthralgia—Doxorubicin—muscle cancer	0.00235	0.00235	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00234	0.00234	CcSEcCtD
Darifenacin—Dyspnoea—Methotrexate—muscle cancer	0.00232	0.00232	CcSEcCtD
Darifenacin—Somnolence—Methotrexate—muscle cancer	0.00231	0.00231	CcSEcCtD
Darifenacin—Dry mouth—Doxorubicin—muscle cancer	0.0023	0.0023	CcSEcCtD
Darifenacin—Dyspepsia—Methotrexate—muscle cancer	0.00229	0.00229	CcSEcCtD
Darifenacin—Confusional state—Doxorubicin—muscle cancer	0.00227	0.00227	CcSEcCtD
Darifenacin—Anaphylactic shock—Doxorubicin—muscle cancer	0.00225	0.00225	CcSEcCtD
Darifenacin—Oedema—Doxorubicin—muscle cancer	0.00225	0.00225	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00225	0.00225	CcSEcCtD
Darifenacin—Infection—Doxorubicin—muscle cancer	0.00224	0.00224	CcSEcCtD
Darifenacin—Pain—Methotrexate—muscle cancer	0.00223	0.00223	CcSEcCtD
Darifenacin—Shock—Doxorubicin—muscle cancer	0.00222	0.00222	CcSEcCtD
Darifenacin—Nervous system disorder—Doxorubicin—muscle cancer	0.00221	0.00221	CcSEcCtD
Darifenacin—Tachycardia—Doxorubicin—muscle cancer	0.0022	0.0022	CcSEcCtD
Darifenacin—Skin disorder—Doxorubicin—muscle cancer	0.00219	0.00219	CcSEcCtD
Darifenacin—Hyperhidrosis—Doxorubicin—muscle cancer	0.00218	0.00218	CcSEcCtD
Darifenacin—Feeling abnormal—Methotrexate—muscle cancer	0.00215	0.00215	CcSEcCtD
Darifenacin—Gastrointestinal pain—Methotrexate—muscle cancer	0.00213	0.00213	CcSEcCtD
Darifenacin—Abdominal pain—Methotrexate—muscle cancer	0.00206	0.00206	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00205	0.00205	CcSEcCtD
Darifenacin—Insomnia—Doxorubicin—muscle cancer	0.00204	0.00204	CcSEcCtD
Darifenacin—Dyspnoea—Doxorubicin—muscle cancer	0.00201	0.00201	CcSEcCtD
Darifenacin—Somnolence—Doxorubicin—muscle cancer	0.002	0.002	CcSEcCtD
Darifenacin—Dyspepsia—Doxorubicin—muscle cancer	0.00198	0.00198	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.00195	0.00195	CcSEcCtD
Darifenacin—Pain—Doxorubicin—muscle cancer	0.00193	0.00193	CcSEcCtD
Darifenacin—Constipation—Doxorubicin—muscle cancer	0.00193	0.00193	CcSEcCtD
Darifenacin—Hypersensitivity—Methotrexate—muscle cancer	0.00192	0.00192	CcSEcCtD
Darifenacin—Asthenia—Methotrexate—muscle cancer	0.00187	0.00187	CcSEcCtD
Darifenacin—Feeling abnormal—Doxorubicin—muscle cancer	0.00186	0.00186	CcSEcCtD
Darifenacin—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00184	0.00184	CcSEcCtD
Darifenacin—Pruritus—Methotrexate—muscle cancer	0.00184	0.00184	CcSEcCtD
Darifenacin—Abdominal pain—Doxorubicin—muscle cancer	0.00178	0.00178	CcSEcCtD
Darifenacin—Diarrhoea—Methotrexate—muscle cancer	0.00178	0.00178	CcSEcCtD
Darifenacin—Dizziness—Methotrexate—muscle cancer	0.00172	0.00172	CcSEcCtD
Darifenacin—Hypersensitivity—Doxorubicin—muscle cancer	0.00166	0.00166	CcSEcCtD
Darifenacin—Vomiting—Methotrexate—muscle cancer	0.00166	0.00166	CcSEcCtD
Darifenacin—Rash—Methotrexate—muscle cancer	0.00164	0.00164	CcSEcCtD
Darifenacin—Dermatitis—Methotrexate—muscle cancer	0.00164	0.00164	CcSEcCtD
Darifenacin—Headache—Methotrexate—muscle cancer	0.00163	0.00163	CcSEcCtD
Darifenacin—Asthenia—Doxorubicin—muscle cancer	0.00162	0.00162	CcSEcCtD
Darifenacin—Pruritus—Doxorubicin—muscle cancer	0.0016	0.0016	CcSEcCtD
Darifenacin—Nausea—Methotrexate—muscle cancer	0.00155	0.00155	CcSEcCtD
Darifenacin—Diarrhoea—Doxorubicin—muscle cancer	0.00154	0.00154	CcSEcCtD
Darifenacin—Dizziness—Doxorubicin—muscle cancer	0.00149	0.00149	CcSEcCtD
Darifenacin—Vomiting—Doxorubicin—muscle cancer	0.00143	0.00143	CcSEcCtD
Darifenacin—Rash—Doxorubicin—muscle cancer	0.00142	0.00142	CcSEcCtD
Darifenacin—Dermatitis—Doxorubicin—muscle cancer	0.00142	0.00142	CcSEcCtD
Darifenacin—Headache—Doxorubicin—muscle cancer	0.00141	0.00141	CcSEcCtD
Darifenacin—Nausea—Doxorubicin—muscle cancer	0.00134	0.00134	CcSEcCtD
